Vorasidenib Expanded Access Program

Neoplasms Clinical Trial

Official title:

The Expanded Access Use of Vorasidenib in Patients With IDH1 or IDH2 Mutated Glioma

Clinical Trial Details — Status: Available

Administrative data

• NCT number: NCT05592743
• Other study ID #: VORA-EAP
• Status: Available

Study information

• Verified date: April 2024
• Source: Servier
• Contact: Servier Pharmaceuticals LLC
• Phone: 1-203-441-7938 (ext. 125)
• Email: expandedaccess[@]servier.com
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

This is an expanded access program to provide vorasidenib for treatment of patients 12 years or older with IDH1- or IDH2-mutated glioma.

Description:

This expanded access program is designed to provide access to vorasidenib for patients with IDH1- or IDH2-mutated glioma who are not eligible for other vorasidenib clinical trials, and who in the opinion of the treating oncologist would potentially benefit from treatment with vorasidenib.

Safety assessments (including vital signs, hematology, and serum chemistry) occur every two weeks for the first two cycles (28 day each cycle), then monthly for the duration of treatment. Treatment with vorasidenib will continue until, in the clinical judgement of the treating physician, the patient is no longer benefiting from the treatment, vorasidenib is approved and available by prescription, or the study is terminated.

Requests by treating physicians to file a single patient investigational new drug application as part of the expanded access program for vorasidenib will be considered on a case-by-case basis.

Recruitment information / eligibility

• Status: Available
• Enrollment: 0
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

1. Male and females; ages = 12 years old.

2. IDH-mutant oligodendroglioma or astrocytoma with the IDH1 or IDH2 gene mutation confirmed by tissue-based diagnosis.

3. At least 1 prior surgery for glioma (including biopsy).

4. Adequate bone marrow function as evidenced by:

• Absolute neutrophil count = 1.5 X 109/L

• Hemoglobin = 9 g/dL

• Platelets = 100 X 109/L

5. Adequate hepatic function as evidenced by:

• Serum total bilirubin = 1.5 X upper limit of normal (ULN)

• Aspartate aminotransferase and alanine aminotransferase: at or below the ULN

• Alkaline phosphatase = 2.5 X ULN

6. Adequate renal function as evidenced by a creatinine clearance (CrCl) = 40 mL/min

Exclusion criteria:

7. Patient is eligible for a clinical trial with vorasidenib.

8. Patients who are enrolled in a Servier-sponsored clinical trial and have completed all requirements of the trial may be eligible if the patient continues to benefit from vorasidenib and does not meet criteria for discontinuation of treatment.

9. Pregnant or breastfeeding.

10. Patients who require or who cannot withhold strong inhibitors of CYP1A2 (ciprofloxacin and fluvoxamine). Consider alternative therapies that are not strong CYP1A2 inhibitors.

Related Conditions & MeSH terms

• Disease Attributes
• Glioma
• Neoplasms
• Neoplasms by Histologic Type
• Neoplasms, Germ Cell and Embryonal
• Neoplasms, Glandular and Epithelial
• Neoplasms, Nerve Tissue
• Neoplasms, Neuroepithelial
• Neuroectodermal Tumors
• Neuroectodermal Tumors, Primitive
• Pathologic Processes
• Recurrence

Intervention

Drug:
• Vorasidenib
Oral therapy

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Servier	Servier Pharmaceuticals, LLC